Orthopedia Stock Price, News & Analysis

OrthoPediatrics Corp. (Nasdaq: KIDS) announced its acquisition of MD Orthopaedics for up to $19.6 million, enhancing its portfolio with a patented solution for treating clubfoot. The deal includes an upfront payment of $8.2 million in cash and $8.9 million in stock, plus $2.5 million in restricted stock vesting over three years. MD Orthopaedics, known for its Ponseti Method bracing systems, has positively impacted 300,000 children globally. By integrating this technology, OrthoPediatrics aims to tap into a $600 million market and expand its reach in non-surgical pediatric orthopedic treatments.

OrthoPediatrics Corp (Nasdaq: KIDS) announced participation in the 21^st Annual Needham Virtual Healthcare Conference. Key executives, including President & CEO Dave Bailey, COO and CFO Fred Hite, and Executive Chairman Mark Throdahl, will engage in a fireside chat on April 12, 2022, at 12:45 PM ET. The event will be accessible via an audio webcast on the company’s investor relations website, with a replay available for 90 days post-event.

Founded in 2006, OrthoPediatrics focuses on pediatric orthopedic advancements, offering 36 surgical systems across trauma, scoliosis, and sports medicine.

OrthoPediatrics Corp. (Nasdaq: KIDS) has announced the limited launch of its innovative PediFlex™ Advanced Interlock Clamp System, enhancing pediatric orthopedic surgeries. This new technology addresses the issue of unwanted flexible nail migration in pediatric patients. The Interlock Clamps are compatible with intramedullary nails sized from 1.5mm to 4.5mm in stainless steel and titanium. The limited commercial launch in the U.S. will precede a global rollout later this year, demonstrating OrthoPediatrics' commitment to advancing pediatric orthopedic solutions.

OrthoPediatrics reported a 31% increase in Q4 2021 revenue, reaching $24.8 million. Full-year revenue reached $98.0 million, up 38% from 2020. Domestic revenue rose 24% while international jumped 150%. Despite an adjusted EBITDA loss of $0.2 million for 2021, it improved by $5.7 million from the prior year. The company guidance for 2022 anticipates revenue between $118 million and $121 million, with positive adjusted EBITDA expected. OrthoPediatrics helped over 38,000 children in 2021, showing strong market demand for its pediatric orthopedic products.

OrthoPediatrics Corp. (NASDAQ: KIDS) was the main sponsor of the 7th Annual International Children’s Spine Symposium held on February 25-26, 2022, in Orlando, Florida. The event featured lectures from renowned international experts and hands-on labs focused on pediatric spine issues. OrthoPediatrics showcased its innovative RESPONSE™ Scoliosis System and FIREFLY Pedicle Screw Navigation Guides. The company also highlighted its ApiFix System, a non-fusion alternative for scoliosis surgery, which is part of its expanding product line, originally acquired in 2020. OrthoPediatrics aims to enhance educational opportunities for pediatric orthopedic professionals.

OrthoPediatrics Corp. (Nasdaq: KIDS) has been named one of the '2022 Best Places to Work in Indiana,' marking the 6th time it has received this honor. The award, organized by the Indiana Chamber of Commerce and Best Companies Group, recognizes companies for their excellent workplace culture. The evaluation process involved a review of workplace policies and an employee survey, with the latter contributing 75% to the final score. The final rankings will be revealed at an awards ceremony on May 12, 2022.

OrthoPediatrics Corp. (KIDS) is set to release its fourth quarter and full year 2021 financial results on March 2, 2022, following market close. The company will host a conference call on March 3, 2022, at 8:00 a.m. ET to discuss the results, accessible via dial-in for both domestic and international callers and through a live webcast on its investor relations page. OrthoPediatrics specializes in pediatric orthopedics, offering 37 surgical systems across key categories including trauma, scoliosis, and sports medicine, with distribution extending to 45 countries.

OrthoPediatrics Corp. (Nasdaq: KIDS) announced preliminary unaudited revenue for Q4 and full year 2021. Q4 revenue is estimated at $24.8 million, a 31% increase from Q4 2020's $18.9 million. Domestic revenue rose 11%, while international revenue surged 363%. Full year 2021 revenue is expected to reach $98.0 million, reflecting 38% growth. Domestic sales grew 24%, and international sales increased 150%. The final financial results will be released in March 2022, as these figures are subject to audit adjustments.